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Summary Atopic dermatitis (AD) is a chronic recurring inflammatory 
skin disease divided into at least two different forms: atopic (extrinsic) 
and non-atopic (intrinsic) dermatitis. Genetic epidemiological studies 
have unraveled several chromosomal loci with putative candidate 
genes, some of which are localized on chromosomes 3, 17 and 20, 
and most recently on 1q21. AD represents a large and continuous 
spectrum of one disease where different contributions from epider-
mal, immunologically relevant genes and their interactions with en-
vironmental signals dictate the outcome of sensitization. AD appears 
early in childhood and has a typical clinical picture with characteristic 
remissions and exacerbations. The variability of the clinical picture is 
related to the complex etiopathogenesis of the disease and patient’s 
age, and is accompanied by moderate to strong itch. This review 
outlines recent standpoints on the etiopathogenesis, diagnosis, treat-
ment and prevention of AD.
Key wordS: atopic dermatitis, children, etiology, pathophysiology, 
clinical evaluation, diagnosis, treatment
IntroduCtIon
Atopic dermatitis (AD) (constitutional neuro-
dermatitis, atopic eczema, endogenous eczema, 
atopic eczema/dermatitis syndrome, AEDS) is a 
chronic recurring inflammation of the skin that can 
occur in all ages but is more common in children. 
The disease is determined by genetic predisposi-
tion localized on chromosomes 1q21, 3, 17 and 
20. Due to the progress in research of AD, a new 
picture emerges in which the natural history of AD 
is divided into three stages: an initial intrinsic form 
(eczema) occurring in early infancy, in 60%-80% 
of cases followed by sensitization to food and/or 
environmental allergens with the development 
of the extrinsic stage (true AD). In this form, it is 
speculated that antigen presenting cells express-
ing the high affinity receptor for IgE (FcεRI) play a 
major role in the control of inflammation. IgE sen-
sitization to self-proteins is observed in children 
and adults with AD. The clinical picture is typically 
characterized by remissions and exacerbations. 
The variability of the clinical picture is related to 
the complex etiopathogenesis and interactions 
with environmental signals and relevant genes, 
age of the patient and itch as well as to the family 
history positive for other atopic diseases such as 
asthma and/or allergic rhinitis (1-7). Atopic eczema 
in childhood is a common disease, the incidence 
of which is increasing (8). AD has been reported to 
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affect 10% of children (9). Although the symptoms 
of AD resolve by adolescence in 50% of affected 
children, the condition can persist into adulthood.
AD is the most common skin disease in chil-
dren. Recent epidemiological studies have shown 
that the prevalence of AD in the 0-7 year age group 
falls within the range of 5%-20%, while in adults 
the incidence, as reported by various authors, is 
between 1% and 3%. AD is equally represented 
in both sexes, although in childhood it more fre-
quently affects boys and in adulthood women. The 
condition typically starts in the first year of life, 
usually between the 3rd and 6th month. Some 60% 
of all AD cases develop before the fifth birthday. 
Just 2% of all AD cases manifest themselves at 
the age of 20 or more years. In around 30% of the 
affected individuals, complete remission occurs by 
the 2nd birthday, in another 30% by the 5th birthday, 
while 10%-15% of patients continue to suffer from 
AD symptoms even after puberty. AD is present 
worldwide and the number of affected people has 
increased in the last three decades, especially 
in the industrialized countries of Europe (10-15). 
From 50% to 80% of AD patients already have or 
develop asthma or allergic dermatitis (16). AD is 
a debilitating condition that can compromise the 
quality of life. Attempts at itch relief by scratching 
worsen the rash, thus creating a vicious circle. 
etIology and pathogeneSIS
The complex etiology and pathogenesis of AD 
remain incompletely understood and are a topic 
of many studies. The prevailing opinion is that the 
pathogenesis of AD is multifactorial. It is believed 
that the development of AD is the result of com-
plex interactions in which genetic and immune fac-
tors (disorders of humoral and cellular immunity as 
well as conditions of the neurovegetative system), 
skin as the barrier (irritation, disorders of the skin 
function), stress (emotional, specific psychogenic 
personality structure) and environmental (climate, 
allergens) factors all play key roles (3,17,18). 
Atopy is caused by multiple polygenic defects. 
If both parents suffer from the same atopic dis-
ease, the child will be affected by the same condi-
tion in 70% of cases. If the parents suffer from dif-
ferent conditions, the child’s chance of developing 
the same disorder is around 30%. The frequency 
of AD in monozygotic twins is around 85%, and in 
dizygotic twins around 21% (13,15). Patients with 
AD inherit abnormalities of the immune response 
linked to multiple chromosomal loci, which explains 
the diversity of the clinical picture. These include 
the abnormality of the locus 5q31-33, which en-
codes interleukins (IL) -3, -4, -5 and -11 as well as 
granulocyte and macrophage colony-stimulating 
factor (GM-CSF); 3q21, which encodes co-stimu-
latory proteins (CD80 and CD86) involved in T-
cell activity; 11q13, which encodes receptors with 
high affinity for IgE antibodies (FceRI); and 1q21, 
17q25 and 20p, which are, together with psoriasis, 
joint candidate genes connected to the control of 
skin inflammation (7,19-24). A wide range of im-
mune abnormalities have been described in pa-
tients with AD. These include T helper 2 (Th2) and 
T helper 1 (Th1) type cell perturbance, elevated 
serum immunoglobulin E (IgE) levels, hyperstimu-
latory Langerhans cells, eosinophilic and elevated 
production of prostaglandin E2 (PGE2) by periph-
eral monocytes (3,5,7,9,17,26).
The pathogenesis of AD includes allergic sen-
sitivity types I and IV as well as the action of leu-
kocytes, monocytes, macrophages, lymphocytes, 
eosinophils, mastocytes and keratinocytes. The 
currently accepted model proposes a predomi-
nant type 2 (Th2) cytokine milieu in the initiating 
stages or acute lesions of AD, and a mixed type 
1 (Th1) and type 2 (Th2) pattern in chronic le-
sions (17,25,27-30). Patients with AD may have 
weakened cellular immunity and regulation of T 
and B lymphocyte activity as well as hyperreactiv-
ity to external antigenic stimuli such as inhalant 
and food allergens and insect antigens. These are 
low-molecular proteins, polysaccharides and hap-
tens. The affected persons show low resistance 
to bacterial, viral and fungal infections. According 
to the current knowledge, the main immune ab-
normality in 80% of all AD cases involves exces-
sive production of IgE proteins with predisposition 
for anaphylactic hypersensitivity and dysregula-
tion of type 1 and 2 cytokines. Such cases are 
termed as ‘extrinsic’ AD, which, in addition to the 
increased IgE levels, is furthermore characterized 
by severe clinical symptoms and chronic pattern. 
Other cases are termed as ‘intrinsic’ AD; they are 
characterized by the same clinical picture but 
show normal levels of total IgE and absence of 
allergen-specific IgE, other atopic conditions and 
negative prick test (29-31). Both forms of AD are 
characterized by eosinophilia that stands in cor-
relation with the severity of the clinical picture. In 
‘extrinsic’ AD, excessive IgE antibodies production 
in the acute stage is a consequence of the acti-
vation of type 2 T-helper cells (Th2). These cells 
produce IL-4, IL-5 and IL-13, and induce differen-
tiation of B lymphocytes and an increase in IgE 
synthesis. In chronic stage, the hyperproduction 
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of IgE is caused by the biphasic model of T-cell 
activation, that is by the combined effect of type 1 
T-helper cells (Th1) and  IL-12-producing Th2 (IL 
12). The production of Th2 type cytokine is linked 
to the membrane expression of glycoprotein CD30 
on CD4+ and CD8+ T-cell clone. As the result of 
the described events, an excessive amount of his-
tamine is released from mastocytes and basophils 
(7,19,22-31). IgE bound to Langerhans cells (Lc) 
via the high-affinity IgE receptor FcεRI is thought 
to bind aeroallergens, food allergens or autoanti-
gens.
Environmental factors that play the key role 
in the development of AD include food, inhalant 
and infectious agents. Food allergens are espe-
cially significant in childhood because they may 
provoke eczematous exanthema in 40% children 
with moderate to severe AD. The most frequent 
food allergens that affect children with moderate 
to severe AD are egg-white, cow milk, peanuts, 
soy, flour and fish (1,3,6,32-34). Inhalant aller-
gens induce peripheral eosinophilia and increase 
serum IgE concentration. The exacerbation of AD 
may be caused by inhalation of or direct contact 
with food allergens. Direct epicutaneous appli-
cation of aeroallergens may induce eczematous 
reaction on unchanged skin in 30%-50% of AD 
patients. The most frequent inhalant allergens are 
house dust and mites, weed and grass pollen, cat 
epithelium and passive smoking (32-38). Patients 
with AD suffer from an increased incidence of bac-
terial, viral and fungal infections, the majority of 
which are located on the skin. In more than 90% 
of all AD cases, Staphylococcus aureus is isolated 
from skin lesions (39). In the healthy population, 
the same bacterium has been found in 5%-15% of 
cases. This bacterium secretes the so-called su-
per-antigens that penetrate the inflamed skin and 
stimulate epidermal macrophages and T-cells. 
Fungal infectious agents affecting patients with 
AD include Trichophyton rubrum, Malassezia fur-
fur and Candida albicans, as well as herpes sim-
plex virus (eczema herpeticatum) and pox virus 
(eczema molluscatum, vaccinatum) (3,6,7,39-46).
The barrier function of the skin plays an im-
portant role in the development of skin lesions in 
AD. In physiological conditions, the skin acts as 
mechanical protection, thanks to corneocytes, as 
well as a permeable barrier, due to the extracel-
lular lipid matrix. In patients with AD the skin loses 
water and contains a high level of free fatty acids 
and sterols; reduced amount of ceramides, gam-
ma-linolenic and dihomo-gamma-linolenic acids 
as well as urea in the corneous skin layer; and 
fewer sebaceous glands. For this reason, the per-
meable function of the skin is disturbed, permit-
ting the entry of allergens, infectious agents and 
irritants (3,4,10,42-46).
The increase in the incidence of AD in recent 
decades cannot be explained by genetic factors, 
which have remained constant, but rather by 
changes in the environment, especially the so-
called “Western lifestyle”. This includes exposure 
to stress, hygiene (too frequent or too aggressive 
washing), vaccination that reduces the contact 
with infectious disease, and finally excessive use 
of antibiotics leading to reduced immunocompe-
tence. A key role is furthermore played by staying 
in air-conditioned or ventilated space, inappropri-
ate clothing, changes in nutrition and food addi-
tives, and exposure to cigarette smoke. Climate 
factors are also important, as a seasonal pattern 
of AD is registered in some 77% of patients, with 
up to 60% suffering from exacerbations in winter 
and up to 15% in summertime (1,3,6,10-12).
ClInICal manIfeStatIonS
The clinical picture of AD shows diversity in its 
morphology, distribution and severity. It ranges 
from mild to extremely severe changes, and it de-
pends primarily on the age but also on the race 
of the patient, frequency of exacerbations, dura-
tion of disease and complications. There are three 
basic types of AD: infantile, childhood and adult. 
Each of them may be accompanied by acute, sub-
acute or chronic skin changes. Acute lesions are 
characterized by the development of papules and 
vesicles on erythematous skin, accompanied by 
intense itch and consequent excoriations, erosions 
and serous exudate. In the subacute type, ery-
thematous, excoriated, scaly papules are found, 
while chronic lesions show lichenification of the 
skin which becomes thick and fibric with papules 
and nodules within the plaques. All three stages 
of skin changes may coexist in the same patient 
(1,2,6-10). Lesions at any stage can develop sec-
ondary infections, which may resemble impetigo, 
with crusting and weeping lesions. Xerosis (dry 
skin) is a characteristic skin finding in AD patients. 
Because xerotic skin is unable to hold moisture, 
it is more likely to develop crack and fissure. The 
resultant skin barrier breakdown increases the 
susceptibility to irritation and infection. When the 
lesions resolve, areas of hyperpigmentation per-
sist.
In infants, clinical manifestations of AD develop 
in the first six months of age, usually around the 
3rd month. They are characterized by the develop-
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ment of symmetric, intensely itchy, erythematous 
macules located primarily on the face and scalp. 
As the disease progresses, macules are trans-
formed into papulovesicles. This is followed by the 
development of infiltrated foci, which may secrete 
and produce scabs, poorly delineated scaly foci, 
erosions, excoriations, and hemorrhagic scabs. 
The changes may spread to the trunk and extremi-
ties, but the area of the nasolabial furrow, nose 
and diaper region are usually spared. This stage 
is often characterized by secondary infections (5-
10,27,45-47).
In children aged 2 to 12 years, AD no longer 
has exudative character and becomes localized. 
At age 2-3 years, the clinical picture becomes in-
creasingly polymorphous. It is characterized by 
the development of characteristic papules and 
plaques localized on the flexion sides of large 
joints: elbows, knees, neck, on the dorsal side of 
the hands and feet, wrists and ankles, cheeks and 
eyelids. They may persist there for long periods of 
time. Some children develop the nummular form of 
AD, which is characterized by coin-sized eczema-
tous changes that may exhibit any of the clinical 
stages of AD and may be located on various parts 
of the body. Later childhood and adolescence are 
characterized by lichenification changes, along 
with hyper- and hypopigmented areas on the flex-
ion sides of large joints, perioral region, nape, 
neck, forehead, thorax, shoulders, hands and feet 
(5,7,10,45-48).
dIagnoSIS
The diagnosis of AD is based on patient his-
tory, clinical examination and laboratory findings. 
Unfortunately, there are no specific laboratory find-
ings or histologic features to define AD. Accord-
ing to Hanifin and Rajka, the clinical picture sup-
ports the diagnosis of AD if at least 3 major and at 
least 3 minor out of 4 major and 23 minor criteria 
for AD are found (27). By contrast, Lillehammer 
bases the diagnosis of AD on the history, clinical 
and laboratory data, along with the set duration of 
the entire disease and each stage (infantile, child-
hood and adult) (3). Pruritus is a universal finding 
in AD on the scalp, neck, wrists and ankles, face, 
cheeks and extensor surface of the extremities 
(antecubital and popliteal fossa). Pruritus can be 
severe, sometimes causing sleep disrupting, irri-
tability and generalized stress for affected patients 
and family members. Pruritus leads to scratching, 
which in turn results in secondary changes such 
as lichenification, excoriation and breakdown of 
the skin barrier. 
The required laboratory tests include the con-
centration of eosinophils, the level of total and 
specific IgE (RIST, RAST), allergy skin tests (prick 
test, scratch test, intradermal, patch or epicutane-
ous test, atopy patch test), immunoelectrophore-
sis and histopathology (2,10,27,48,52).
dIfferentIal dIagnoSIS
The differential diagnosis in the infant must first 
exclude infantile seborrheic dermatitis, then num-
mular eczematous dermatitis, contact dermatitis, 
scabies, psoriasis, dermatophytosis, reaction to 
medicaments, and atopiform dermatitis (5-10).
treatment
The treatment of AD targets underlying skin 
abnormalities. Patients should be educated about 
the chronic nature of the disease and the need for 
continuous skin care. Xerosis is one of the key 
elements in the treatment of AD. Lubricants and 
topical corticosteroids are the mainstays of thera-
py. If pruritus does not respond on antihistamines, 
microbial overgrowth (bacterial or viral) should 
be considered. The treatment of AD must be in-
dividually adjusted to the patient and must take 
into account his/her age, stage of the disease, 
extent and localization of changes, presence of 
superinfection, and previous response to treat-
ment. Modern treatment principles are based on 
the attempt to sufficiently hydrate the skin, elimi-
nate the itch, inflammation and infection, if pres-
ent, and to prevent sensitization. The treatment 
may be classified into topical, systemic and pho-
totherapy (1,2,5-10,16,48,49,53-69). Alternative 
medicine has been termed as a means of therapy 
that has no scientific basis, but such medicine is 
increasing without the benefit of controlled clinical 
trials on the subject (64-66). In childhood eczema 
alternative therapies are reported: Chinese herbs, 
homeopathy, dietary restriction, massage therapy, 
hypnotherapy, and evening primrose oil. Alterna-
tive therapies are often used by pediatric derma-
tology patients (64). 
local therapeutic procedures include adequate 
hydration of the child’s skin, which consists of the 
use of pH neutral soap and minimal degreasing 
effect during regular bathing. Bathing with warm 
(not hot) water must be as short as possible (5-10 
min) except for oil baths in which water tempera-
ture should be by two degrees lower than usual. 
After “three-minute” bathing the skin should be 
treated with moisturizers/emollients, sometimes 
several times a day because they significantly 
alleviate itching and have an antiphlogistic effect 
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(48,53). Ointments are preferred to creams and lo-
tions, but they are greasy and are poorly tolerated. 
The frequency of their use depends on the level of 
skin dryness: the drier the skin, the more occlusive 
emollients should be used. Severely affected skin 
can be optimally hydrated by occlusion in addi-
tion to the application of an emollient. Small areas 
can be occluded with plastic wrap; the hands can 
be covered with gloves. However, this occlusive 
technique is not used with topical corticosteroids 
because of side effects. Soaks in sodium bicar-
bonate or colloidal oatmeal (Aveno) can be used 
to treat pruritus (16). Products with urea, omega 
fatty acids, lipids, zinc and copper are usually 
used in the treatment of AD, as they retain water in 
the corneous layer. Indifferent hydrophilic creams 
(oil/water emulsion) should be used in the acute 
stage, antiphlogistic creams and soft pastes in the 
subacute stage, and ointments (water/oil) and tars 
in the chronic stage of AD. In mild cases these 
preparations alone provide sufficient therapeutic 
effect (5,6,48,53-55). To avoid skin scratching, fin-
gernails should be cut short. 
Topical therapy for inflammatory stage of AD is 
based on the use of corticosteroids. The strength 
of products is adjusted to the severity of symp-
toms, so that the least potent but sufficiently effec-
tive product in a suitable base is applied. These 
products have anti-inflammatory, antimitotic and 
antiproliferative effects. They should be used in-
termittently in exacerbations, with a diary of use. 
As soon as the condition improves, corticosteroids 
should be substituted with emollients because in 
long-term use they may cause skin atrophy. 
Using wet-wrap dressing with diluted steroids 
and/or emollients (WWT) is relative safe addition 
to the therapeutic treatment options in adults with 
severe and/or refractory AD. Specialized nursing 
care is essential, especially when using WWT for 
prolonged periods (59). 
The greatest penetration occurs with steroid 
use on the groin and face; the longest penetra-
tion occurs with the application on the palms and 
soles. In children it is reasonable to use initially a 
group 6 or 7 (low potency) steroids for intertrigi-
nous areas. A general principle in treating AD in 
children with topical steroids is to use the least 
potent agent possible and to limit the frequency 
of application. The use of low-potency topical ste-
roids is appropriate for non-intertriginous areas 
in children and adults. If the dermatitis is severe 
and a more potent steroid is needed, the patient 
should be closely monitored and the strength of 
steroid should be reduced as the skin lesions im-
prove (1,16,48,53-56). Tar preparations are effec-
tive alone or with topical corticosteroids. Frequent 
superinfections of the skin, especially with Staphy-
lococcus, may indicate the need to use local an-
tibiotics (e.g., mupirocin) alone or combined with 
corticosteroids (7,49,53,56).
Recently introduced preparations in AD ther-
apy include local immunomodulators: calcineurin 
inhibitors tacrolimus (as 0.01% and 0.03% oint-
ment) and pimecrolimus (as 1% cream). These 
are the first immunosuppressive drugs that act 
locally on a specific immune event. By inhibiting 
calcineurin, they inhibit inflammatory cytokines 
and thus act selectively on T-cell activation and 
antigen-presenting cells. They are suitable for lo-
cal therapy because, in contrast to corticosteroids, 
they do not cause skin atrophy; they are poorly 
absorbed through skin; and no cases of systemic 
toxicity have been hitherto registered. These prep-
arations are indicated for use in moderate and se-
vere cases of AD (57-61).
Systemic therapy of AD includes the use of 
antihistamines (62), corticosteroids, antibiotics 
and antiviral drugs as well as immunotherapy and 
phototherapy (16,63,67-69). The main purpose 
of antihistamines with sedative and non-sedative 
effect in AD (loratadine, terfenadine, diphenhydr-
amine, astemizole, cetirizine, hydroxyzine) is to al-
leviate itch. More effective are sedating agents but 
they can effect the child’s ability to learn. Tricyclic 
antidepressants such as doxepin (Sinquan) and 
amitriptyline (Elavil) also have an antihistaminic 
effect, induce sleep and reduce pruritus (16). Topi-
cal forms of antihistamines are not recommended. 
In children, short-term systemic use of corticoste-
roids, most frequently prednisone, is indicated for 
severe treatment-resistant cases and cases of 
acute AD. Because of the risk of rebound, their 
dose and therapy duration should be accurately 
titrated. Marked symptoms of superinfection are, if 
necessary, treated with systemic antibiotics (ceph-
alosporins) and antiviral medication acyclovir (Zo-
virax) to prevent complications. In severe clinical 
pictures or in treatment-resistant cases, the treat-
ment will include immunosuppressive drugs, in 
the first place cyclosporine (2.5-5 mg/kg/day for 
8 weeks), which selectively inhibits IL-2 synthe-
sis, as well as azathioprine (Imuran 2.5-3.5/day), 
and methotrexate. Interferon-gamma is effective 
in AD treatment, mycophenolate-mofetil, thalido-
mide, leukotriene inhibitors zafirlukast (Accolate 
in children older than 12 years), and montelukast 
(Singulair in children older than six years), Thymo-
pentin, anti IgE antibodies and topical phospho-
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diesterase inhibitors (Cipampylline 0.15% cream) 
and IVIG failed to show any significant beneficial 
effect in severe AD (67). 
A particularly effective treatment is photothera-
py, used in treating refractory AD to induce kera-
tinocytes to produce anti-inflammatory cytokines, 
which in turn leads to reduction in lymphocyte 
count, mastocyte degranulation, Malassezia furfur 
and Staphylococcus aureus growth inhibition, and 
increase in epidermal lipid synthesis (67). UVA 
and UVB are used alone or in combined (UVA and 
UVB) in the form of narrow band UVB and PUVA 
therapy as well as extracorporeal photopheresis 
(16,53,54,63). In 2005, a group of experts pub-
lished a proposal for treatment of AD in children 
and adults (68). In very severe cases of AD ac-
companied by some serious complications, the 
authors have good results with topical corticoste-
roids (0.3% prednisone valerate acetate), oral ke-
totifen fumarate and sodium cromoglycate (69).
Finally, the elimination of trigger factors has 
therapeutic significance. It is necessary to avoid 
clothes that may irritate the skin (wool, synthet-
ics), heat and sweating. Depending on the results 
of allergy tests, patients should avoid exposure to 
specific allergens (certain foods, house dust mite, 
animal hair and feathers) and cleansing agents 
that may irritate the skin. They should also avoid 
longer stay in smoky and air-conditioned spaces. 
ConCluSIon
AD is a chronic relapsing skin disease that 
typically occurs in early childhood and in pediat-
ric population, and has a complex etiology and 
pathogenesis. The manifestation of the disease, 
its severity and extent of skin lesions may vary 
considerably among patients. As different cases 
often exhibit variation in laboratory parameters, a 
precise definition of AD requires a consensus on 
new criteria, which should take into account recent 
knowledge about the etiopathogenesis of the dis-
ease. With the constant increase in the prevalence 
of the disease in mind, the importance of preven-
tion, early diagnosis and optimal treatment must 
be stressed. While further development of safer 
and more effective treatment is necessary, a pre-
condition for successful treatment of AD remains 
appropriate skin care. 
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You can have brownish, healthy skin by using Nivea cream; year 1936.
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